The FDA on June 14, 2024, approved BLINCYTO® for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-Cell Precursor Acute Lymphoblastic Leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy. BLINCYTO® is a product of Amgen Inc.
Bottom Ad
Advertisement
Subscribe
